Burden of Depression among Working-Age Adults with Rheumatoid Arthritis

Deb, Arijita; Dwibedi, Nilanjana; LeMasters, Traci; Hornsby, Jo Ann Allen; Wei, Wenhui; Sambamoorthi, Usha

doi:10.1155/2018/8463632

Cited by 14 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RA is a chronic autoimmune disease characterized by progressive joint damage and multiple comorbidities that may lead to impaired physical function, diminished overall quality of life, and mortality. Long-term treatments that are safe and efficacious are needed to reduce disease symptomology, to prevent irreversible joint damage, and to reduce the burden of disease from comorbidities [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study

et al. 2020

View full text Add to dashboard Cite

Objective To evaluate the long-term efficacy of once-daily baricitinib 4 mg in patients with active RA who were either naïve to DMARDs or who had inadequate response (IR) to MTX. Methods Analyses of data from two completed 52-week, phase III studies, RA-BEGIN (DMARD-naïve) and RA-BEAM (MTX-IR), and one ongoing long-term extension (LTE) study (RA-BEYOND) were performed (148 total weeks). At week 52, DMARD-naïve patients treated with MTX monotherapy or baricitinib 4 mg+MTX in RA-BEGIN were switched to open-label baricitinib 4 mg monotherapy; MTX-IR patients treated with adalimumab (+MTX) in RA-BEAM were switched to open-label baricitinib 4 mg (+MTX) in the LTE. Patients who received placebo (+MTX) were switched to baricitinib 4 mg (+MTX) at week 24. Low disease activity (LDA) [Simple Disease Activity Index (SDAI) ≤11], clinical remission (SDAI ≤ 3.3), and physical functioning [Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ 0.5] were assessed. Data were assessed using a non-responder imputation. Results At week 148, SDAI LDA was achieved in up to 61% of DMARD-naïve patients and 59% of MTX-IR patients initially treated with baricitinib, and SDAI remission was achieved in up to 34% of DMARD-naïve patients and 24% of MTX-IR patients; HAQ-DI ≤ 0.5 was reached in up to 48% of DMARD-naïve patients and 38% of MTX-IR patients initially treated with baricitinib. Over 148 weeks, 3.6% and 10.7% of MTX-IR patients discontinued across treatment groups due to lack of efficacy or due to adverse events, respectively; discontinuation rates were similar in the DMARD-naïve population. Conclusion Treatment with baricitinib 4 mg demonstrated efficacy for up to 3 years and was well tolerated.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Similar results have been reported in a previous cross-sectional study conducted at a multi-center level in India, which reported high prevalence of depression in a young adult age group of 40–59 years, patients with RA [ 26 ]. Among previous studies from India that evaluated RA prevalence, the National Mental Health Survey (NMHS) study revealed high prevalence of RA with depression among patients aged 40–59 years compared to older adults [ 27 ]. Age-stratified analysis also suggests that the depressive disorders are more prevalent among patients with RA in young age (40–55 years) in Indian adults [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Patterns and prevalence of psychiatric morbidity among individuals with rheumatoid arthritis

Khan,

Nabi,

Parrey

et al. 2024

Reumatologia

View full text Add to dashboard Cite

ObjectivesRheumatoid arthritis (RA) is a chronic autoimmune disorder that affects the joints, causing inflammation, pain, and potential joint damage. Patients with RA are at high risk of developing psychiatric morbidity; it is important to recognize these psychiatric manifestations. The relationship between psychiatric symptoms and RA is complex and can involve various factors, including the impact of chronic pain, inflammation, medications, and the overall burden of managing a chronic illness. Aim of the study was to systematically investigate and analyze the patterns and prevalence of psychiatric morbidity among individuals diagnosed with RA, with the aim of identifying common mental health conditions, understanding the interplay between RA and psychiatric disorders, and providing valuable insights for improved holistic patient care.Material and methodsThis was a prospective, observational cross-sectional study conducted over a period of three years in patients with RA. Psychiatric morbidity was assessed using International Classification of Diseases-10 criteria and Mini-Plus by dedicated psychiatrists. The diagnosis of RA was confirmed using the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) diagnostic criteria for RA and the disease activity was calculated by Disease Activity Score with 28-joint count (DAS28) using the calculator from the RheumaHelper application. The data were analyzed using SPSS, version 23.0.ResultsA total of 1,000 patients with RA were included in this study. Nearly two-thirds of the patients were female (64.8%). The majority of patients belonged to the age group of 41 to 54 years. Total 47.5% of the patients were unemployed, 27.0% were salaried, 19.0% were businessman, while 6.5% of the patients were students. More than half of the patients (53.2%) had moderate disease activity. Major depressive disorder was the most commonly observed comorbidity (41.0%), followed by somatoform disorder (28.5%), and generalized anxiety disorder was found in 13.5%. No psychiatric manifestations were found in 17% of studied individuals.ConclusionsPsychiatric morbidity is associated with RA and there is a need for psychiatric services to be made available to these patients.

show abstract

“…In chronic inflammatory diseases, comorbid depression is common. Among RA patients, prevalence of depression ranges from 14-48% [41][42][43] and is associated with higher levels of pain and disability, lower health-related quality of life, and increased mortality [44]. Evidence suggests a role of pro-inflammatory cytokines including interleukin (IL)-6, TNF-alpha, and IL-1 in promoting depression, and indeed, patients with severe RA have a higher risk of depression [45][46][47][48][49].…”

Section: Discussionmentioning

confidence: 99%

Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database

et al. 2020

View full text Add to dashboard Cite

Background and Objective Golimumab is a fully human anti-tumor necrosis factor monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This study estimated rates of prespecified outcomes in patients with RA, PsA or AS initiating golimumab versus matched patients initiating nonbiologic systemic (NBS) medications. Methods Patients enrolled in a US health plan with rheumatic disease who initiated a study medication were accrued between April 2009 and November 2014. Golimumab initiators were matched by propensity score to NBS initiators in a 1:4 ratio. Outcomes were identified through September 2015. As-treated, as-matched, and nested case-control (NCC) analyses were conducted in the matched cohorts. Sensitivity analyses evaluated the impact of residual confounding and nondifferential misclassification of exposure and outcomes. Results Risks of outcomes were similar between golimumab and NBS initiators. In the as-treated analysis, the rate ratio (RR) for depression was elevated during current golimumab use versus golimumab non-use in the NBS cohort [RR 1.45, 95% confidence interval (CI) 1.31-1.61]. This finding was not replicated in as-matched (RR 1.08, 95% CI 0.97-1.19) or NCC (odds ratio 1.01, 95% CI 0.78-1.31) analyses, which focused on incident cases. Sensitivity analyses suggest that depression was sensitive to misclassification, and the RR changed from greater than to less than one across a plausible range of specificity. Conclusions This study suggests that there is no association between exposure to golimumab and an increased risk of prespecified outcomes. Increased depression risk in the as-treated analysis was not replicated in other analyses and may be associated with residual imbalance in baseline history or severity of depression.

show abstract

Burden of Depression among Working-Age Adults with Rheumatoid Arthritis

Cited by 14 publications

References 33 publications

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study

Patterns and prevalence of psychiatric morbidity among individuals with rheumatoid arthritis

Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database

Contact Info

Product

Resources

About